differentiated antibiotics

Cempra Initiates Phase 3 Clinical Trial in Patients with Uncomplicated Gonorrhea Infection

CHAPEL HILL, N.C., Aug. 12, 2014 -- Cempra, Inc., (Nasdaq: CEMP) today announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.


Cempra, Inc. Reports Second Quarter 2014 Financial and Operating Results

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the second quarter and six months ended June 30, 2014.